The BJP expects authors to share data by Christopher, George
BJP update on data sharing_October 2019 
 1 
The BJP expects authors to share data  
Christopher H. George1 
Stephen P. H. Alexander2 
Giuseppe Cirino3 
James R. Docherty4 
Daniel Hoyer5, 6, 7 
Paul A. Insel8 
Angelo A. Izzo3 
Yong Ji9 
Reynold A. Panettieri10 
Christopher G. Sobey11 






1 Swansea University, UK 
2 University of Nottingham, UK 
3 University of Naples Federico II, Italy 
4 Royal College of Surgeons in Ireland, Dublin, Ireland 
5 The University of Melbourne, Australia 
6 Florey Institute of Neuroscience and Mental Health, Australia 
7 The Scripps Research Institute, La Jolla, USA 
8 University of California, San Diego, USA 
9 Nanjing Medical University, Nanjing, China 
10 Rutgers University, USA 
11 La Trobe University, Bundoora, VIC, Australia 
12 University College London, UK 
13 The University of British Columbia, Canada 
14 University of Reading, UK 
15 Federal University of Minas Gerais, Belo Horizonte, Brazil 
16 William Harvey Research Institute, Queen Mary University of London, London, UK 
 
Conflict of interest 
The authors declare no conflicts of interest. 
 
17 Correspondence 
Amrita Ahluwalia, British Journal of Pharmacology, The Schild Plot, 16 Angel Gate, City Road, London 
EC1V 2PT, UK. Email: info@bps.ac.uk 
  
BJP update on data sharing_October 2019 
 2 
The need for an update 
The BJP has recently implemented several policies to improve the rigour and transparency of 
experimental design, analysis and data reporting (Alexander et al., 2018;Curtis et al., 
2018;Docherty et al., 2019). This Journal has also developed checklists to help authors comply 
with the BJP’s submission requirements on experimental design and reporting (Declaration, 
2018a), animal experimentation (Declaration, 2018b) and immunoblotting and 
immunohistochemistry (Declaration, 2018c). The editors recognize also that a keystone in the 
process of improving further the transparency and openness in reporting scientific progress is 
to make raw data compliant with FAIR principles (i.e. be findable, available, interoperable 
and reproducible (FAIR, 2019)). The Senior Editorial Team at BJP is committed to supporting fully 
initiatives that open up data-sharing as widely as possible. 
In 2017, we considered issues on data-sharing relevant to pharmacology research. We 
concluded that, at that time, no digital solutions existed to enable the integration of published 
findings with the underpinning raw data for the types of approaches typically published in the 
BJP (George et al., 2017). With due consideration of the practical limitations and fallibilities of 
available repositories and archiving systems, and issues on data storage and transfer, we 
adopted a policy of encouraging authors to share their data. This position did not 
unnecessarily burden authors with having to comply with systems for data sharing that we 
decided were not fit for purpose. However, we pledged to provide an update in due course 
and this editorial reviews the rationale for expecting data sharing for articles published in BJP 
and provides guidelines for authors to comply with this expectation. 
 
BJP data sharing survey: views from the editorial board 
Although there have been helpful guidelines introduced to facilitate the maintenance of 
digital data (UK Research and Innovation, 2015;Hart et al., 2016), the development of web-
based systems for the indexing, structuring, sharing and curation of research data have not 
matured to the extent that might have been anticipated. Reconciling the acknowledged 
benefits of sharing research data with the current mechanisms for doing so remains a 
challenge. So that we could better gauge how the BJP could maintain its compliance with 
policies that promote data availability and sharing (Committee on Publication Ethics, 
2019;Centre for Open Science 2019), whilst recognizing real practical limitations and also 
serving the needs of authors publishing in this Journal, the views on data-sharing of the full 
editorial board of the BJP were sought. The Figure shows the responses to a survey that posed 
questions that concerned data acquisition, sharing, structuring and storage. We contend that 
due to the international nature of the BJP editorial board (representation from 23 different 
countries) that these responses also give insights into the collective perspectives from across 
the global pharmacology research community. 
 
Summarizing key points: 
• The breadth of activities in the pharmacology community probably precludes a ‘one-
size fits all’ solution to data sharing (Q1). Finding common ground in relation to standardisation 
of data format and annotation is likely to be exceptionally difficult. 
• Raw data are typically stored using a variety of media, some of which pose challenges 
for transferability and digitization (Q2). 
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• Almost two-thirds of respondents (65%) presently make their data available but most 
(59%) have never requested raw data from others (Q3 and Q4).  
 
• Sharing all data pertaining to a published paper is not commonplace, and substantial 
efforts would be required to overcome the barriers to enabling this (Q5, Q6 and Q7). 
 
• Nearly one-fifth of respondents expressed serious concerns on the potential for their 
shared data to be misused (Q6). Making data available should not mean that the data can 
be reused for any purpose by whomever has accessed them. How consent/permissions from 
the originators of shared data, for the subsequent use of their data, might be regulated 
remains a complex and unresolved problem. 
 
• Assigning who should hold overall responsibility for all data generated as part of 
collaborative working remains a challenge (Q8). 
 
The survey served to reinforce the view that the pharmacology community is fully engaged 
with the ethos of data-sharing and availability. However, major efforts- that include 
developing policy on who should organise, standardise, support and pay for data-sharing- are 
required if it is to become a seamless part of the publishing experience.  
 
 
Enabling a flexible way of making data available 
Following a constructive collaboration among the editors of the BJP, Wiley, our publisher, and 
the British Pharmacological Society (BPS), we have now produced a data sharing policy that 
appropriately considers the landscape of research data and attitudes to sharing amongst 
pharmacology researchers. We believe that this new policy- one that enables multiple ways to 
share data- has the requisite flexibility as a simple, workable solution for authors to make 
available data compliant with ‘level 1’ of the Transparency and Openness Promotion (TOP) 
(Centre for Open Science, 2019). As shown in the Table, an appropriate statement can be 
selected from templates among several options regarding the sharing of data.  
Authors might want simply to make data available on request. This option is likely to be 
most attractive to many authors seeking to publish in the BJP, since it obviates problems 
inherent in making some of their ‘non-digital’ / ‘non-standard’ research data available using 
an externally hosted resource (e.g. an online repository). 
Authors though may choose to archive the supporting data, from which the published 
results are derived, in a public repository that offers guaranteed preservation. For help in 
choosing a suitable repository, please see: Registry for Research Data Repository,2019. We 
strongly discourage the use of data repositories that do not assign a Digital Object Identifier 
(DOI) and regard the impermanence of such archiving resources as a cause for real concern.  
It is important to stress that this policy update does not mandate that data are shared. If 
there are legitimate reasons that prevent the sharing of some data described in the 
manuscript, for example for legal or ethical reasons, or simply that authors do not wish to share 
data, then the inclusion of a statement to this effect is appropriate. However, if authors do not 
choose to share data- and their paper includes a statement to this effect- there would still be 
an expectation that all raw data supporting papers published in the BJP would be retained for 
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a minimum of 10 years (or 20 years for clinical data) as per the Concordat on Open Research 
Data (Concordat, 2016;Committee on Publication Ethics, 2019).   
 
 
What does this change in policy mean for authors? 
The BJP now expect that authors will make data available under one or more of the 
mechanisms set out in the Table. All accepted manuscripts will be required to include for 
publication a data availability statement selected from one of the templates listed in the Table 
and the Instructions to Authors. Authors will be required to confirm adherence to this data 
policy on submission of their manuscript.  All statements will be placed in the heading of the 
manuscript, in front of all firewalls. When data are available and electronically linked to the 
source, authors will need to provide a citation of the data in their reference list. For further 
information, please see our Instructions to Authors (British Journal of Pharmacology, 2019). We 
thank the BJP editors for their assistance in completing the survey and authors for their 
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Figure. Survey of BJP editorial board on data sharing and availability. 
Survey was conducted online in February 2019. N=57 respondents. 





Table. Template statements on data availability 







Availability of data Template for data availability statement 
Data available on request 
from the authors 
The data that support the findings of this study are available from the 
corresponding author upon reasonable request. Some data may not be 
made available because of privacy or ethical restrictions.  
Data openly available in 
a public repository that 
issues datasets with DOIs 
The data that support the findings of this study are openly available in 
[repository name] at http://doi.org/[doi], reference number [reference 
number]. 
Data subject to third party 
restrictions 
The data that support the findings of this study are available from [third 
party]. Restrictions apply to the availability of these data, which were used 
under license for this study. Data are available [from the authors / at URL] 
with the permission of [third party]. 
Data sharing not 
applicable – no new data 
generated* 
Data sharing is not applicable to this article because no new data were 
created or analysed in this study. 
Data not shared No data have been shared. 
